Two compounds target drug-resistant brain cancer cells in laboratory tests

by Indian Institute of Technology Gandhinagar

edited by Gaby Clark, reviewed by Robert Egan

Gaby Clark

Scientific Editor

Meet our editorial team
Behind our editorial process

Robert Egan

Senior Editor

Meet our editorial team
Behind our editorial process Editors' notes

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

fact-checked

peer-reviewed publication

proofread

The GIST Add to Preferred Sources

Cancer remains among the most deadly diseases worldwide. Globally, more than 300,000 new cases of brain cancer are reported each year, with glioblastoma, an aggressive form of brain cancer, accounting for over 250,000 deaths. The current standard of care involves the use of temozolomide (TMZ), a chemotherapy medication. However, the tumor can be difficult to control because cancer cells evolve to evade the effects of such treatments. Thus, finding new ways to target these cells is an important area in cancer research.

Research from the Indian Institute of Technology Gandhinagar (IITGN) explores one such possibility of tackling drug-resistant glioblastoma. It highlights two promising candidates that can target tyrosine threonine kinase (the TTK or Mps1 protein), which is integral to cell division. High levels of this protein have been linked to glioblastoma progression. The results have been published in the Journal of Biological Chemistry and RSC Medicinal Chemistry.

Interrupting the quality control inspector

Biological cells have tightly regulated systems for distributing genetic material. TTK helps manage one of the checkpoints, and its job is to ensure that chromosomes are properly handled as a cell divides. Upon spotting a mistake during cell division, TTK triggers a safety alarm that causes the process to pause while the repair takes place. Once everything is in the right place, TTK gives the green light, and the cell divides successfully.

Since cancer cells divide at a much faster rate than normal cells, they rely heavily on TTK to survive their chaotic division cycles. The researchers asked whether disrupting this checkpoint could make it harder for glioblastoma cells to manage the damage to their DNA. It can reduce their viability and enhance their sensitivity to treatments like radiotherapy.

Gaurav Rai said, "Earlier studies have linked TTK's involvement in resistance to TMZ, a commonly used chemotherapy drug. We wanted to explore whether modifying a candidate from one of our previous studies, J54 (a selective inhibitor of TTK), could help us target TTK more effectively and guide further research into ways of tackling drug-resistant glioblastoma." The first author of this study, Rai, is a doctoral student in the Chemistry Department at IITGN and the recipient of the Prime Minister's Research Fellowship.

The chosen ones

Laboratory experiments revealed that SPK17 (mentioned in the paper as G17) stood out among more than 10 compounds developed by the researchers in one part of the study. Compared to TMZ, the SPK17 concentration associated with a 50% reduction in glioblastoma cell viability (IC50) was approximately 176 times lower for LN229 cells and 85 times lower for U87MG cells, which are two human glioblastoma cell lines.

What was more interesting was that SPK17 produced approximately eight times the cell-death signal when tested at 10 micromolar, compared with 200 micromolar TMZ in the case of glioblastoma cells that had become resistant to TMZ under experimental conditions (LN229-TMZ-R cells).

SPK17b (mentioned in the paper as G17b) was the most prominent among the five compounds in the other part of the study. Compared to TMZ, the IC50 for SPK17b was approximately 81 times lower for LN229 cells and 59 times lower for U87MG cells. Further, the concentration of SPK17b needed to produce the cell-death signal in LN229-TMZ-R cells was substantially lower when tested at 10 micromolar, compared with 200 micromolar TMZ.

In other words, less SPK17 and SPK17b were needed to kill 50% of brain cancer cells compared to the routine chemotherapeutic drug, suggesting a promising lead.

Second author of the other study, Deepika, added, "We also realized that SPK17b appeared to do more than slow the growth of glioblastoma cells. The treated cells showed an impaired ability to metastasize or spread, one of the hallmarks of cancer." Deepika is also a doctoral student in the Chemistry Department at IITGN. Together, these results suggest that the two compounds may interfere with several processes that help tumor cells survive and multiply.

Sharing his thoughts on the mechanism involved, Rai explained, "Both compounds act on the same protein, TTK, but the two studies followed different consequences of blocking it. SPK17 removes a built-in pause that normally gives a dividing cell time to mend its damaged DNA. The cell is pushed through division with the damage unrepaired, and it accumulates until the cell dies.

"SPK17b instead causes a buildup of reactive oxygen species, toxic byproducts of the cell's own metabolism, until the cell's defenses are overwhelmed and it self-destructs, while also leaving surviving cells less able to move and invade surrounding tissue."

The road ahead

Drug discovery should be viewed as a journey with several checkpoints of its own. A compound must first show that it can affect the intended biological target. The next step should be to establish whether the candidate is effective in progressively complex biological systems and whether its benefits outweigh its risks.

According to professor Sivapriya Kirubakaran, "When you are working on a disease as aggressive as glioblastoma, you are aware of how urgently better treatment options are needed. Findings like those from our study can bring us closer to asking the right questions to improve understanding of difficult diseases. Our two compounds give us a mechanism-based therapeutic strategy to investigate how we might target drug-resistant tumor cells. Future studies to understand the efficacy of the molecules in animal studies are ongoing."

Kirubakaran is the Kankuben Bakshirambhai Gelot Chair Professor in the Chemistry Department at IITGN and heads the Cancer Chemical Biology lab at the institute.

Publication details

Gaurav Rai et al., Rewiring mitotic checkpoint control via Mps1 inhibition overcomes DNA repair-mediated resistance in glioblastoma, Journal of Biological Chemistry (2026). DOI: 10.1016/j.jbc.2026.113487

Gaurav Rai et al., Development of phenothiazine-based inhibitors towards drug-resistant glioblastoma, RSC Medicinal Chemistry (2026). DOI: 10.1039/d6md00465b

Journal information: Journal of Biological Chemistry

Key medical concepts

Temozolomide

Clinical categories

OncologyNeurology Provided by Indian Institute of Technology Gandhinagar Who's behind this story?

Gaby Clark

MA in English, copy editor since 2021 with experience in higher education and health content. Dedicated to trustworthy science news. Full profile →

Robert Egan

Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →

Citation: Two compounds target drug-resistant brain cancer cells in laboratory tests (2026, November 6) retrieved 7 November 2026 from https://medicalxpress.com/news/2026-11-compounds-drug-resistant-brain-cancer.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.